<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531401</url>
  </required_header>
  <id_info>
    <org_study_id>CCA-FTS-201</org_study_id>
    <nct_id>NCT00531401</nct_id>
  </id_info>
  <brief_title>Study of Salirasib to Treat Non-Small Cell Lung Cancer</brief_title>
  <official_title>Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concordia Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concordia Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Salirasib is effective to shrink or prevent
      the growth of the tumors associated with non-small cell lung cancer in both patients who are
      newly diagnosed or have recurrent disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of non-progression (as reflected in the tumor control rate of percent patients with CR+PR+SD) defined as the number of patients whose tumor did not progress (&lt;20% tumor increase to total disappearance of tumor according to RECIST)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salirasib</intervention_name>
    <description>600mg BID until disease progression or unacceptable toxicity occurs.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Non-Small Cell Lung Cancer not amenable to curative therapy with surgery or radiation

          -  Measurable disease

          -  Adenocarinoma of the lung, have not received prior chemotherapy for the malignancy and
             has a ≥ 15 pack year history of smoking; OR previously treated with recurrent disease
             and documented KRAS mutation

          -  Last dose of radiotherapy &gt; 3 weeks prior to study entry and recovered from all acute
             toxicities associated with the prior therapy

          -  No history of another malignancy in the past 5 years except treated non-melanomatous
             skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix

          -  Karnofsky Performance status of 70 or greater

          -  Body Weight &gt; 50 kg

          -  Life expectancy ≥ 3 months

          -  Serum Creatinine ≤2.0 mg/dL, total bilirubin ≤ 2.0 mg/dL, ALT and AST ≤ 3x ULN,
             alkaline phosphatase ≤ 5x ULN, WBC &gt; 3000/mm³, ANC ≥ 1500/mm³, platelets ≥
             100,000/mm³, hemoglobin ≥ 10g/dL.

          -  No coexisting cardiac or medical problems that would limit compliance in the study

          -  Willing to undergo blood sampling for pharmacokinetic analysis

          -  Negative pregnancy test, if applicable

        Exclusion Criteria:

          -  Evidence of active heart disease including myocardial infarction within previous 3
             months

          -  Active infectious process

          -  Active central nervous system metastases (requiring increasing doses of
             corticosteroids over the prior month, known progressing lesions)

          -  Pregnant or lactating

          -  Major surgery without full recovery or major surgery within 3 weeks prior to treatment
             start

          -  QTc Interval &gt; 470 msec

          -  Gastrointestinal tract disease resulting in inability to take or absorb oral
             medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory J Riely, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Victor Bauer</name_title>
    <organization>Concordia Pharmaceutical</organization>
  </responsible_party>
  <keyword>Non-Small-Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Farnesylthiosalicylic acid</mesh_term>
    <mesh_term>Salicylates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

